×

RNS Number : 0186M

Tracsis PLC

03 January 2019

 

3 January 2019

Tracsis plc

("Tracsis" or the "Group")

 

Significant Contract Win

 

Tracsis plc, a leading provider of software and services for the traffic data and transportation industry, is pleased to announce that it has signed a significant five year Framework Agreement with a major Train Owning Group for its TRACS Enterprise product.  The Agreement covers all of the Operator's individual Train Operating Companies (TOCs) within the UK plus other franchises that the Owning Group may win in future. 

The total potential value over the duration of the Framework Agreement is expected to be multi million pounds although given the 'call off' nature of the Agreement, the number of modules used and the specific timing of implementation (and therefore revenue) is difficult to forecast with certainty.  However, the Directors believe this is a key win for Tracsis that will lead to significant recurring revenue opportunities within the duration of the Agreement and beyond.  For the avoidance of doubt, at this point in time there will be no change made to current year forecasts.

 

Enquiries:

Tracsis plc                                                                                                                                    Tel: 0845 125 9162

John McArthur, CEO

Max Cawthra, CFO

finnCap Ltd                                                                                                                                   Tel: 020 7220 0500

Christopher Raggett/Scott Mathieson, Corporate Finance

Andrew Burdis, Corporate Broking

The information communicated in this announcement is inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

Notes to editors: 

§The Group specialises in solving a variety of data capture, reporting and resource optimisation problems along with the provision of a range of associated professional services.

§Tracsis' products and services are used to increase efficiency, reduce cost and improve the operational performance and decision making capabilities for clients and customers. 

§The Company offers the following services:

–  Rail Technology & Services: Software and technology led consulting, and remote condition monitoring: Industry strength software that covers a variety of asset classes working alongside consulting and related professional services across the operational and strategic planning horizon, plus technology and reporting for critical infrastructure assets in real time, to identify problems and aid with preventative maintenance.

–  Traffic & Data Services: Collation, analytical services, and event management within traffic and pedestrian rich environments.  The business provides technology and data that is instrumental in the development of 21st century intelligent transport systems and smart cities.

§Tracsis has a blue chip client base which includes all major UK transport owning Groups.  The business also works extensively with Network Rail, the Department of Transport, TfL, multiple local authorities, major outdoor music and sporting events, and a wide variety of large engineering and infrastructure companies.

§The business drives growth both organically and through acquisition and has made ten acquisitions since 2008.

§For more information on Tracsis please visit http://www.tracsis.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTSSFESEFUSEEF

Close

×

Neville Registrars is delighted to welcome Gamfook Jewellery Plc as the newest addition to its list of client companies.

 

Gamfook Jewellery Plc is a custom jewellery designer and retailer in China offering a range of personalised goods and gifts under the brand name of “Gamfook”.  

 

Further information can be found on the Company's website: http://www.gamfook.net

 

 

Close

×

RNS Number : 2043L

Water Intelligence PLC

21 December 2018

 

 

Water Intelligence plc 

Sydney Water Win

Water Intelligence plc (AIM: WATR.L) (the "Company" or "Water Intelligence"), a leading multinational provider of precision, minimally-invasive leak detection and remediation solutions for both potable and non-potable water is pleased to kick-off 2019 early with a significant municipal contract win in Sydney, Australia.

A few weeks ago, the Company provided a trading update for Q3 that reinforced its previous 1H guidance on strong growth for 2018.  We noted that our overall trajectory was approximately 40% sales growth with the mission of "sustainable multinational growth" for 2019 and beyond. With this municipal win in Australia, accompanied by recent smaller municipal wins in the US in Michigan and New York, the Company is off to a good start to meet its 2019 growth plan.  

The contract in Sydney is a multi-year contract anticipated to contribute approximately US$1 million to 2019 sales.

Executive Chairman, Patrick DeSouza commented, "Despite market volatility, our fundamentals remain strong.  Demand for water infrastructure solutions will continue to grow worldwide. Full steam ahead."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014

 

For further information about this announcement please contact:

Water Intelligence plc    Patrick DeSouza, Executive Chairman                    Tel: +1 203 654 5426

finnCap Ltd                 Julian Blunt / Giles Rolls (Corporate Finance)
Camille Gochez (Corporate Broking)                      Tel: +44 (0)20 7220 0500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTTMBJTMBMTTTP

Close

×

RNS Number : 0474L

LightwaveRF PLC

20 December 2018

 

20 December 2018

LightwaveRF plc

(AIM: LWRF)

 

The Smart family uses Lightwave

 

 

LightwaveRF plc ("LightwaveRF", "Lightwave" or "the Company"), the leading smart home solutions provider, is pleased to announce that it has launched its first, fully integrated digital above-the-line consumer campaign, focused on the UK market.

 

The campaign features a series of videos showing the Smart family appreciating the benefits of Lightwave intelligent lighting. The campaign is using social media, YouTube and programmatic advertising to specifically target consumers interested in smart home technology. The new videos can be viewed through the Company's blog page: https://lightwaverf.com/blogs/news/meet-the-smarts and the Company's website page on smart lighting: https://lightwaverf.com/pages/smart-lighting.

 

Through its other marketing channels, Lightwave continues to generate excellent reviews in the specialist consumer product media. Lightwave lighting kit scored 4.4/5 in a recent review by tech publication Smart Home Geeks, which said: "This is a different approach to smart lighting and prevents the problem most smart lights have, that when the switch is off the bulb becomes dumb. Where this solution really comes into its own is it connects to the rest of the Lightwave range, allowing heating, power and presence automation."

 

This endorsement comes as the Company's own customer reviews, on the Trustpilot platform exceeded 100, with an average score of 7.3 equating to a 4 star 'Great' rating in Trustpilot's classification system. 

 

Commenting on the campaign launch, Jason Elliott, Chief Executive, said: "This targeted digital campaign is part of our plan to bring the brand to a mass market audience. Our aim is to capture consumers who are aspiring to have a smart home and show what can be done with Lightwave products. Our revised marketing strategy is having a real positive impact on the brand and we look forward to more success with this campaign."

 

 

For further information:

 

LightwaveRF plc Jason Elliott, CEO Kevin Edwards, CFO	www.lightwaveRF.com +44 (0) 121 250 3625
Stockdale Securities Limited Tom Griffiths/Edward Thomas	www.stockdalesecurities.com +44 (0) 20 7601 6100
Yellow Jersey PR Charles Goodwin/Annabel Atkins	www.yellowjerseypr.com +44 (0) 7747 788 221

 

About LightwaveRF

 

LightwaveRF plc ("LightwaveRF", "Lightwave" or "the Company"), is the UK's only fully integrated home automation company.

 

New customers typically buy a starter pack of Link Plus hub and smart dimmer which has Apple HomeKit compatibility, 2-way communication and built-in energy monitoring. Later adding other easy to install devices from the Lightwave range enables further in-home control, monitoring and automation of lighting, heating and power.

 

Devices may be operated manually, by smartphone or tablet-based apps and also through Google Assistant and Amazon Alexa voice control.

 

Leading tech industry publication 9to5 Mac describes Lightwave as "the best UK HomeKit solution for smart lighting".

                                                         

For further information and "Newsletter sign up", please visit:

www.lightwaverf.com/corporate/

                                                    

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRADDBDDUXBBGIC

Close

×

RNS Number : 0462L

Midatech Pharma PLC

20 December 2018

 

 

 

 

 

 

 

 

20 December 2018

Midatech Pharma PLC

("Midatech", "Company" or "Group")

 

Midatech Announces Q-Sphera™ Microsphere Technology Partnership

–      Collaboration agreed with major regional pharmaceutical company

–      Midatech's leading technology will be used in development and evaluation with a key clinical program

–      Further validates Q-Sphera™ sustained release drug delivery technology

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, today announces an agreement with a major regional corporation ("the Partner"), in which the Partner will evaluate Midatech's Q-Sphera™ microsphere sustained release technology for use with the Partner's materials.

 

Under the collaboration agreement, the Partner will conduct a feasibility program using Midatech's Q-Sphera™ technology. No financial terms have been disclosed.

 

The agreement follows the positive clinical 'proof-of-concept' in August this year for Q-Sphera™ as a sustained release drug platform in the MTD201 first-in-human study. This study was a key inflection and validation point for both the Q-Sphera™ technology, as well as its application in a therapeutic product MTD201 for carcinoid cancer and acromegaly.

 

Q-Sphera™ is the next generation micro-encapsulation and polymer-depot sustained release (SR) drug delivery platform developed by Midatech using a novel and disruptive printing-based process, with significant and distinct advantages over conventional technologies.  From a manufacturing perspective Q-Sphera™ is an improved precise, scalable, efficient, and environmentally friendly microparticle manufacturing platform. From a clinical profile perspective it ensures homogenous microparticles that release active drug compounds into the body in a linear, well controlled and predictable manner over an extended period of time. Finally, from a convenience perspective Q-Sphera allows simpler and quicker reconstitution, improved injectability and less painful injections due to the smaller needle size required.

 

The global controlled release market size is in the order of $32bn, and the current market for sustained release microsphere products is approximately $6bn pa1 which includes blockbuster drugs for oncology, hormonal disorders, autoimmune diseases, various mental health disorders, alcohol/ drug dependence and pain management.

 

Commenting on the announcement, Dr Craig Cook, Chief Executive Office of Midatech Pharma, said: "We are delighted to announce this partnership with a leading global pharmaceutical corporation.  This marks another important step in the development of our impressive Q-Sphera™ technology, after the positive clinical 'proof of concept' first-in-human study earlier this year in carcinoid cancer and acromegaly. Together with partnerships such as the one being announced we are focused on increasing our traction in the sustained delivery market, where we hope to establish Q-Sphera as the leading platform.  Our innovative sustained release technology has the potential to improve the efficacy, safety and convenience of existing drugs by enabling improved clinical release profiles of drugs. We look forward to the results of this feasibility collaboration, as well as further developing the platform and working with this partner and others looking to capture a share of the multibillion dollar market for sustained release treatments."

 

1 Transparency; Grandview; GlobalData Research

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Craig Cook, CEO

+44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate finance: Freddy Crossley / Emma Earl

Corporate broking: James Stearns

+44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Nicholas Brown / Angela Gray

+44 (0)20 3709 5700

[email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

+1 339 970 2843

[email protected]

 

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech Pharma (LSE AIM: MTPH; NASDAQ: MTP) is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing a range of improved chemo~therapeutics or new immuno~therapeutics, using its three proprietary platform drug delivery technologies, all of which are in the clinic, specifically: 

1.    Q-Sphera™ platform: our disruptive polymer microsphere technology used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months.

2.    MidaCore™ platform: our leading edge gold nanoparticle technology used for targeting sites of disease at the nanoscale i.e. i. chemotherapy – improved and targeted delivery of existing chemotherapeutic agents to tumour sites, as well as ii. immunotherapy – enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells

3.    MidaSolve platform: our innovative nanosaccharide technology used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumours

Each of our three technologies are thus focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can exert their actions in an effective, safe and precise manner.

Midatech is headquartered in Oxfordshire, with an R&D facility in Cardiff and a manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

AGRFKCDDDBDBFBD

Close

×

RNS Number : 8897K

Osirium Technologies PLC

19 December 2018

 

 

For immediate release

19 December 2018

 

Osirium Technologies plc

 

("Osirium" or "Group")

 

Contract win with major international provider of Financial Services

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with a leading international provider of fiduciary and administration services.

 

Under the terms of the contract Osirium will deliver its full PxM Platform including the Privileged Account Management, Privileged Task Management and Privileged Session Management modules and associated consultancy services.  The initial licence is for 400 devices and is set to run for 39 months.

 

The Osirium solution is being implemented to address a range of business and operational challenges, including:

 

·     automating tasks to simplify and secure routine and frequently-used activities, as well as to deliver time and cost savings;

·     providing control over internal access for system administrators and shared partner logins;

·     controlling and protecting passwords against Phishing and Malware attacks;

·     auditing and monitoring user access and activity to demonstrate compliance with GDPR and other regulations.

 

David Guyatt, Chief Executive Officer, commented: "Osirium is delighted to have been awarded this contract. The wide range of business challenges and use cases that we will be addressing  demonstrates the continuously increasing value our innovative approach to cybersecurity delivers to customers."

 

–      Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah / Alex Price
Yellow Jersey PR (Financial PR) Sarah Hollins Henry Wilkinson	Tel: +44 (0)7764 947 137 Tel: +44 (0)7951 402 336

 

 

Notes to Editors:

 

About Osirium

Osirium Technologies plc (AIM: OSI.L) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Management ("PAM") software. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

 

Osirium has defined and delivered what the Directors view as the next generation PAM solution.  The team has developed the concept of a Virtual Air Gap to separate users from passwords.  Built on Robotic Automation technology, Osirium's Privileged Task Management module further strengthens Privileged Account security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers.

 

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016.  For further information please visit www.osirium.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTBLBDDISBBGII

Close

×

RNS Number : 5868K

FireAngel Safety Technology Group

17 December 2018

 

17 December 2018

 

FireAngel Safety Technology Group plc

("FireAngel" or the "Company")

 

Contract wins

 

FireAngel (AIM: FA.), one of Europe's leading developers and suppliers of home safety products, announces that it has secured agreements to supply mains and battery-powered smoke and heat alarms to two housing associations in Scotland.

 

The Company will supply River Clyde Homes, a not-for-profit affordable housing provider with 5,800 homes, with a mix of mains and battery products. It has also signed a two-year agreement with Caledonia Housing Association, which owns and manages over 4,000 homes, to supply a mix of mains and Wi-Safe 2 battery alarms, which are all compatible with the Company's connected home solutions. This contract, along with the previously announced contract with Queens Cross Housing Association, has been secured through the Scottish Procurement for Housing framework.

 

Following changes to the Housing (Scotland) Act, expected to be enacted early in 2019, all homes in Scotland will require:

·    sealed long-life battery or mains-wired alarms that are interlinked;

·    one functioning smoke alarm in the room that is frequently used by the occupants in the daytime;

·    one functioning smoke alarm in every circulation space on every floor;

·    one heat alarm in every kitchen; and

·    a carbon monoxide alarm will also need to be fitted in each room with a carbon-fuelled appliance or flue.

 

FireAngel's Wi-Safe 2 wireless interlink alarms ensure that each property achieves constant compliance through the use of interlinked alarms installed in the kitchen, hallway and living room. Additionally, FireAngel's unique monitoring platform, FireAngel Connect, allows for remote monitoring and instant notifications.

 

Neil Smith, Group Chief Executive of FireAngel, commented: "We are delighted to have signed two further contracts with housing associations in addition to our Queens Cross Housing Association agreement. Our alarms are designed to provide the highest level of protection at all times and to ensure compliance with the imminent new legislative changes requiring interlinked alarms in all properties. It is encouraging to see housing associations in Scotland recognising the imminent implementation of legislation and the need to ensure the products they are seeking to install are compliant with the upcoming regulations."

 

 

For further information, please contact:

 

FireAngel Safety Technology Group plc	02477 717 700
Graham Whitworth, Executive Chairman
Neil Smith, Group Chief Executive
Stockdale Securities Limited	020 7601 6100
Tom Griffiths
Vigo Communications	020 7390 0233
Jeremy Garcia / Fiona Henson / Charlie Neish

 

Notes to Editors

 

About FireAngel Safety Technology Group plc ("FireAngel")

 

FireAngel's mission is to protect, save and improve our customers' lives by making innovative, leading edge technology simple and accessible.  FireAngel is one of the market leaders in the European home safety products market and launched its own connected homes product proposition at the end of 2016. 

 

FireAngel's principal products are smoke alarms, CO alarms and accessories.  The Company has an extensive portfolio of patented intellectual property in Europe, the US and other selected territories.  Products are sold under FireAngel's leading brands of FireAngel, FireAngel Pro, AngelEye and FireAngel Connect.

 

For further product information, please visit: www.fireangeltech.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAFFSFMLFASEDE

Close

×

RNS Number : 6039K

Concepta PLC

17 December 2018

 

17 December 2018

Concepta Plc

("Concepta" or the "Company")

myLotus® successful UK launch

 

Concepta Plc (AIM: CPT), the innovative UK healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market is pleased to advise on the successful launch in the UK of its breakthrough myLotus®  product for women's fertility.  

myLotus® allows women to self-test to identify their optimal fertile days thereby improving their chances of naturally getting pregnant. myLotus® enables women to monitor their fertile phase as part of their menstrual cycle and is the only home test to 'quantitatively' measure personalised hormone levels and the 'rate-of-change' of these levels preceding ovulation to help aid a natural conception. Users measure, record and track their hormone levels and follow their fertility journey in an accompanying free downloadable app.  

Whilst awareness, profile and sales of the myLotus® device are just commencing, feedback from early users and fertility bloggers has been very positive can be viewed online at www.myLotus.com

Discussions have also commenced with 'Key Opinion Leaders' to advise on the wider use of myLotus® especially for women who wish to carefully monitor their hormonal levels and for those who have previously struggled to conceive naturally, enabling an alternative for couples prior to considering more costly IVF treatment.   

In addition to the growing myLotus® digital UK presence, the Company is preparing plans for the roll-out of myLotus® across Europe under its CE-mark approval. Commercial discussions have also commenced with retail providers to make myLotus® more broadly available across the UK.

Matthew Walls, Chairman said: "Although marketing and communications around myLotus® are just beginning, feedback from the early users has been exceptional. We will be raising awareness of the value of the myLotus® device and its window on fertility over the coming months via an increased online presence, Key Opinion Leaders and marketing of our initial fertility case studies. Further details can be viewed at www.myLotus.com."

 

Enquiries

Company: www.conceptaplc.com, Product: www.myLotus.com

Matthew Walls, Chairman

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

Novum Securities

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles Tel: +44 (0) 774 884 3871

 

About Concepta Plc:

Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on increasing a woman's chances of getting pregnant naturally and for unexplained infertility in women.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF typically not offered until two years. Research indicates couples start to take positive action ahead of this time with little medical support to help them do so.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

PRLUNUKRWOAUAAA

Close

×

RNS Number : 5651K

Xeros Technology Group plc

17 December 2018

 

RNS Reach

17 December 2018

 

Xeros Technology Group plc

 

MARKEN establishes a unique position in US firefighter's personal protective equipment servicing market

 

Xeros Technology Group plc (AIM: XSG, 'Xeros', 'the Group'), the developer and provider of water saving technologies with multiple commercial applications, today announces that MARKEN, its North American high performance workwear business specialising in the cleaning, inspection and repair of firefighter's personal protective equipment ('PPE'), has become the only Independent Service Provider ('ISP') in North America to secure UL DQS ISO ISO-9001 registration, recognising the company's highest standards of quality management.

 

The UL DQS ISO ISO-9001 registration has been secured for each of MARKEN'S sites in North America: North Las Vegas, Nevada; Austell, Georgia; Medley, Florida and Corona, California.

 

Additionally, MARKEN has become one of only a handful of ISPs to secure verification under both US National Fire Protection Association ('NFPA') 1851 and 1855 standards, covering structural, proximity and technical rescue PPE used by fire departments. The verifications allow MARKEN to clean, decontaminate, inspect and repair every element of a firefighter's PPE such as jackets, trousers, boots and helmets, using Xeros' unique, patented technologies.

 

Joey Beeman, General Manager of MARKEN commented:

 

"The welfare of the more than a million permanent and volunteer firefighters across the US is of paramount importance to us in developing MARKEN's service offering. With serious concerns about how firefighters are repeatedly exposed to dangerous situations and toxic carcinogens while in the line of duty, it's more important than ever to ensure their protective clothing and equipment is effectively cleaned, decontaminated and maintained to ensure it is kept in prime condition.

 

"Securing ISO registration recognises that MARKEN is driving up standards across the US market for the cleaning and maintenance of firefighter's clothing and specialist protective equipment.

 

"With both ISO and NFPA verification, MARKEN is rapidly establishing a reputation as the market leader in the US for the cleaning and maintenance of firefighter PPE.

 

"We are seeing considerable interest from fire departments across North America – acknowledging the clear benefits of MARKEN's higher standards of operation and Xeros' unique cleaning technologies in developing cost-effective and sustainable solutions for the cleaning and decontamination of firefighter PPE."

 

MARKEN is the only service provider operating in coast-to-coast locations in North America to hold UL DQS ISO 9001 registration and both UL NFPA 1851 and 1855 verification.

 

 ENDS

 

Enquiries:

 

Xeros Technology Group plc   Mark Nichols, Chief Executive Officer   Paul Denney, Chief Financial Officer	Tel: 0114 321 6328
Jefferies International Limited (Nominated Adviser and Joint  Broker)   Simon Hardy / Will Soutar	Tel: 020 7029 8000
Berenberg (Joint Broker)   Chris Bowman / Ben Wright / Laure Fine	Tel: 020 3207 7800
Instinctif Partners   Adrian Duffield / Kay Larsen/ Chantal Woolcock	Tel: 020 7457 2020

 

Notes to Editors

 

Xeros Technology Group plc (LN: XSG) is a platform technology company that is reinventing water intensive industrial and commercial processes.

 

Xeros' uses its patented XOrbTM technologies to significantly reduce the amount of water used in a number of major applications with the remaining water becoming far more efficient in either affixing or removing molecules from substrates such as fabrics and garments. The result being significant improvements in economic, operational and sustainability outcomes.

 

Xeros has three divisions working in the garment finishing (Textile Technologies), tanning (Tanning Technologies, branded Qualus) and cleaning/laundry (Cleaning Technologies) markets. In cleaning/laundry, the company has three applications covering domestic laundry, commercial laundry (branded "Hydrofinity") and the cleaning of high performance workwear (branded "Marken").

 

For more information, please visit – http://www.xerostech.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRABXBDDXGBBGIS

Close

×

RNS Number : 3171K

Integumen PLC

13 December 2018

 

13 December 2018

 

Integumen plc

 

("Integumen" or "the Company")

Labskin-On-A-Chip to monitor real-time skin related diseases and Labskin-AI data analysis to predict the best course of treatment

Integumen is pleased to announce a cross-platform biophysics agreement with AI developer, Rinocloud Limited, in association with Cork Institute of Technology's Nimbus embedded systems research institute and its Cappa Photonics Laboratory to develop Labskin-On-A-Chip ("LOAC") technology.

 

Labskin-On-A-Chip (LOAC)

Pioneering animal free, clinical research skin-treatment test platform by exploiting Photonics. Labskin is grown on a microchip where light is generated, detected and manipulated, using the cutting-edge use of lasers and fibre-optics on an electro-optical device.

 

Labskin is already a valuable tool for our pharma and skin care clients:

·      Laboratory grown human skin used for testing of skin products and treatments,

·      Can be populated with harmful viruses,

·      Tested using natural skin conditions with good and bad bacteria from patients.

 

LOAC real-time and hands-free can monitor: 

·      Bacteria and virus growth or decline on Labskin – human skin,

·      Balance of good and bad bacteria during skin treatments,

·      The impact on the skin's microflora of skin care products and treatments.

 

RinoLab AI Software:

Combined with the RinoLab/Labskin AI software tools, analysis of the data via Labskin AI client portal can be fed into pharmacodynamic in-silico (pharmaco-dynamic/pharmaco-kinetic) models and used in the pharmaceutical clinical research sector. For clinical research the long-term data accumulated will provide clinical data for new products and skin treatments.

 

World first in skin treatment clinical research. 

Labskin-on-a-Chip as a pre-clinical and post-clinical platform is a major step up for all skin related disease treatments. The completion of the project over the next 12 months is expected to provide every dermatology clinic with a desktop ability to take a swab of the patient's own bacteria, place it on the Labskin and provide the best course of treatment.

 

Fin Murray CEO of Rinocloud commented:

"This is an exciting cross platform development in artificial intelligence at Rinolab and Rinocloud. Our collaboration with Labskin for the AI platform and our work with educational institutions who use Rinocloud has opened up a major opportunity that is set to transform the lives of 3% of the population who suffer daily from skin diseases."

 

Gerard Brandon CEO of Integumen commented:

"Right time, right place, right people, right technology and the right thing to do. In the short time we have been working with the team at Rinocloud we have identified many synergies that bringing together biology, physics, software and most importantly a can-do attitude. I look forward to working closely with the team to rolling this out in late 2019."

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 122 392 6660
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Hybridan LLP  (Broker)	Claire Noyce	+44 (0) 20 3764 2341

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCUUUWRWVAUAAA

Close